人参茎叶皂苷联合盐酸小檗碱在抑制乳腺癌术后复发及转移中的临床疗效分析

The effects of ginsenoside capsules and berberine hydrochloride on the prognosis of mammary cancer

目的:研究人参茎叶皂苷与盐酸小檗碱联合用药对乳腺癌术后肿瘤复发和转移的临床抑制效果。方法:选取我科室2005年1月至2007年12月收治疗的确诊为乳腺癌并行手术治疗的患者共100例,按随机数字表发分为治疗组和对照组各50例,治疗组在常规化疗的基础上给予人参茎叶皂苷与盐酸小檗碱辅助治疗,对照组术后给予西药常规化疗,在治疗后12月、治疗后24月、治疗后36月、治疗后48月和治疗后60月随访并记录两组患者的KPS日常功能状态评分及两组患者肿瘤复发及转移情况,采用统计学方法对数据进行分析。结果:两组患者KPS功能状态评分:治疗组治疗后12月、24月、36月、48月、60月KPS评分分别为(72.05±2.0、76.25±2.5、79.89±1.9、82.56±2.3、86.14±2.7)分,均高于对照组(65.32±2.1、69.55±1.8、73.44±2.2、77.55±2.4、80.55±2.6)分,且差异均有显著性。治疗组治疗后12月、24月、36月癌胚抗原(CEA)水平分别为(77.21±2.01、10.56±2.11、10.18±1.98)ng/ml均优于对照组(9.32±1.91、14.89±2.33、13.55±2.19)ng/ml,且差异均有显著性。治疗组治疗后12月、24月、36月癌抗原125(CA125)水平分别为(47.33±5.01、59.62±6.79、61.38±7.41)u/ml均优于对照组(9.32±1.91、14.89±2.33、13.55±2.19)u/ml,且差异均有显著性。(4)5年后治疗组共9例患者出现肿瘤复发和转移低于对照组(19例),且差异有显著性。(5)治疗60个月后治疗组无复发生存率与总生存率分别为(82%、94%)均高于对照组(62%、80%),且差异均有显著性。治疗组中位生存时间为(71.2±3.01)月,高于对照组中位生存时间(65.7±2.13)月,且差异有显著性。(6)治疗组副反应发生情况为(恶心呕吐5例、腹泻3例、厌食7例、白细胞降低8例),对照组为(恶性呕吐6例、腹泻3例、厌食6例、白细胞降低7例),无明显差异性。结论:人参茎叶皂苷与盐酸小檗碱联合应用能提高乳癌患者术后生存质量,能明显提高患者的五年生存率降低乳癌手术复发及转移的几率,与常规西药化疗相比无明显副反应,值得临床进一步研究和应用。

Objective： To observe and study the effect of ginsenosides and berberine hydrochlofide tobreast tumor recurrence and metastasis inhibi- ting. Methods： 100 patients who diagnosed with breast cancer from January 2005 to December 2007 ,were randomly divided into 50 patients. the treatment group received total ginsenoside and berberine hydrochloride adjuvant therapyon the basis of conventional chemotherapy, the control group medicine given conventional chemotherapy, following-up and recording KPS score and tumor recurrence and metastasis of the two groups, using statistics methods for data analysis. Results： The two groups of patients KPS score ： After treatment in December, 24 months, 36 months, 48 months, 60 months KtX3 score was （72.05 ± 2.0,76.25 ± 2.5,79.89 ± 1.9,82.56 ± 2.3,86.14 respectively ± 2.7） were higher （65.32 ± 2.1,69.55 ± 1.8,73.44 ± 2.2,77.55 ± 2.4,80.55 ± 2.6）, and the differences were statistically significant （p 〈0.05）. Treatment group in December, 24 months, 36 months CEA125 level （47.33 ± 5.01,59.62 ± 6.79,61.38 ± 7. 41 ）, respectively, after treatment u / ml were better than the control group （9.32 ± 1.91,14.89 ± 2.33,13.55 ± 2.19） u/ml, and the differences were statistically significant （ p 〈 0.05）. 5 years after treatment group, 9 patients had tumor recurrence and metastasis than the control group （19 cases）, and the difference was statistically significant （p 〈 0.05）. 5years after the treatment group, 9 patients had tumor recurrence and metastasis than the control group （ 19 cases）, and the difference was statistically significant （p 〈 0.05）. The treatment group recurrence-free survival and overall survival rates were （82%, 94% ） ,were higher （62%, 80% ）, and the differences were statistically sig- nificant （ p 〈 0.05 ）. median survival time otTreatment group was（71.2 ± 3.01 ） months higher than the median survival time （65.7 ± 2.13 ） months, and the difference was statistically significant （ p 〈 0.05）. Conclusion： It can improve the quality of life after breast cancer, and im- prove the five-year survival rate of patients reduce the risk of recurrence for the combination of ginsenoside and berberine hydrochloride, com- pared with conventional western medicineno obvious side effects. It is worthy of further research and application.